The report evaluates the analytical validity, clinical validity, and clinical utility of the VeriStrat test, a liquid biopsy-based proteomic test that identifies a chronic inflammatory immune response indicative of aggressive disease in patients with advanced non-small cell lung cancer (NSCLC) and is intended to provide prognostic information to assist physicians with patient treatment and monitoring choices.
If you have a Hayes login, click here to view the full report on the Knowledge Center.